Results 251 to 260 of about 143,596 (340)

Mechanistic Insights Into Photocatalytic Materials for Toxic Pollutants: Environmental Remediation of Personal Care Products

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Photocatalytic materials have emerged as promising solutions for environmental applications due to their ability to degrade organic pollutants under sunlight or artificial light. In this review, recent progress on the photocatalytic materials used for the degradation of pharmaceutical personal care products (PPCPs) in environmental ...
Urvashi Sen, Gunjan Chauhan, Surbhi Soni, Monika Vats, Anand Kumar, Indra Bahadur   +5 more
wiley   +1 more source

Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries.

BMJ
Duru O, Santoni G, Holmberg D, Birgisson H, Kauppila JH, von Euler-Chelpin M, Ness-Jensen E, Lagergren J.   +7 more
europepmc   +1 more source

Prescribing practices for proton pump inhibitors among primary care physicians in England: an evaluation. [PDF]

BJGP Open
Plehhova K, Wray J, Aluko P, Sutton S, McArdle J, Dawson A, Coyle C, Stevens RM.   +7 more
europepmc   +1 more source

RAPID HEARTBURN RELIEF WITH PROTON PUMP INHIBITOR: HYPE OR REALITY

, 2005
Kenneth R. DeVault
openalex   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors. [PDF]

Eur J Clin Pharmacol
Shang H, Mao H, Wang J, Tian X, Zheng K, Wang J.   +5 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients. [PDF]

Basic Clin Pharmacol Toxicol
Weir KR, Tombez C, Mattmann Y, Zambrano SC, Ferguson E, Jungo KT, Zangger M, Volken S, Vallejo-Yagüe E, Lüthold RV, Schulthess-Lisibach AE, Bieri C, Barbier M, Juillerat P, Streit S, Inauen J.   +15 more
europepmc   +1 more source

Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions

, 2022
Franciosi JP, Mougey EB, Dellon ES, C Gutierrez-Junquera, S Fernandez-Fernandez, Venkatesh RD, Gupta SK   +6 more
openalex   +1 more source

A New Era for Using Natural Pigments: The Case of the C50 Carotenoid Called Bacterioruberin

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Haloarchaea are extremophilic microorganisms belonging to the Archaea domain that require high salt concentrations to live, thus inhabiting ecosystems like salty ponds, salty marshes, or extremely salty lagoons. They are more abundant and widely distributed worldwide than initially expected.
Micaela Giani, Elena Valdés, José María Miralles‐Robledillo, Guillermo Martínez, Carmen Pire, Rosa María Martínez‐Espinosa   +5 more
wiley   +1 more source